As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

近年来，默沙东投入巨资扩大产品组合，减少对Keytruda的依赖。2023年，该公司斥资近110亿美元收购了生产自身免疫性疾病治疗药物的Prometheus Biosciences Inc.，并与Daiichi Sankyo ...

Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...

Its offerings include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI. On May 22, ESPR and Daiichi Sankyo Europe GmbH announced the ...

BASKING RIDGE, N.J., November 13, 2024--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and ...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November ...

Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia and a leader in radiopharmaceutical ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...